Friday, August 29, 2014
Inquirer Daily News

Teva will be leaner, but doesn't specify job cuts

Teva Pharmaceuticals officials said the company will narrow its focus on which drugs it makes and cut about $1 billion from its production and procurement costs in the next five years, but there was no word on layoffs at Philadelphia area facilities such as the factory in Sellersville, Bucks County.

Teva will be leaner, but doesn't specify job cuts

Teva Pharmaceuticals Ltd. officials said Tuesday the company will narrow its focus on which drugs it makes and cut about $1 billion from its production and procurement costs in the next five years, but there was no word on layoffs at Philadelphia area facilities such as the factory in Sellersville, Bucks County.

“More and more we will focus on cost-effective locations,” Carlo de Notaristefani, Teva’s chief of global operations, said during the company’s three-hour presentation to stock market analysts in New York.

Based in Israel but with its Americas headquarters in North Wales, Teva sells more generic drugs than any company in the world. But it is trying to increase its more-profitable branded drug business, while helping its stock price that slumped in recent years. Teva closed Tuesday at $41.67, down 85 cents on the New York Stock Exchange.

In 2010, Teva shifted some production from Sellersville to its plant in Forest, Va., and some of the 500 people employed at that time lost jobs. As of Tuesday, Teva’s main division had 10 production plants in the U.S., more than any other country.

Chief executive officer Jeremy Levin, who took over May 9, said greater focus of effort, whether it be areas of drug research or efficiency in production and procurement, will be how the company returns greater value to shareholders.

“Where we cannot make a difference, we will not try to make a difference,” Levin said, referring to choices on drugs.

Levin and other officials touted the company’s top-selling, brand-name drug Copaxone, which is used by patients with multiple sclerosis. Teva is fighting off competitors who hope to eventually sell generic versions of the injectable medicine or the oral versions under development. Copaxone is part of the central nervous system (CNS) group of medicines, one area that Teva will focus on more in the future.

Painkillers are part of that group and, as Teva research and development chief Michael Hayden said, “Pain is the number one complaint bringing patients to their doctors in the U.S.”

To that end, Teva said it will pay Xenon Pharmaceuticals Inc. $41 million up front and as much as $335 million for a drug now-called XEN402, which is in clinical development for a variety of painful disorders.

 

David Sell
About this blog
David Sell blogs about the region's pharmaceutical industry. Follow him on Facebook.

For Inquirer.com. Portions of this blog may also be found in the Inquirer's Sunday Health Section.

Reach David at dsell@phillynews.com.

David Sell
Business Videos:
Also on Philly.com:
Stay Connected